IRVING, Texas, Nov. 5 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today said the upcoming presentation on DelSite Biotechnologies, Inc., its wholly-owned subsidiary, will be webcast live from the Kennedy I Room at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at New York City's Palace Hotel on Wednesday, November 7th, at 2:00 pm Eastern Time.
The presentation will cover DelSite's three key platform technologies in the areas of drug delivery and vaccine adjuvants. The Company will also provide an update on the development status of DelSite's lead product candidate. To access the webcast, please log on to the following website: http://www.wsw.com/webcast/rrshq12/carn.pk.
DelSite Biotechnologies specializes in the development of novel liquid and powder formulations for protein/peptide therapeutics and vaccines using its proprietary platform technologies. So far this year, DelSite has signed six technology rights evaluation agreements with commercial partners and institutions that are interested in its delivery technology.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,
biopharmaceutical and consumer products company currently utilizing
naturally-occurring complex carbohydrates to manufacture and market
products for mucositis, radiation dermatitis, wound and oral care, as well
as to manufacture and market the nutraceutical raw material Manapol(R) and
cosmetic raw material Hydrapol(TM). Carrington also manufactures and
markets consumer products and manufactures quality products for other
companies. Manufacturing operations comply with cGMP standards.
Carrington's DelSite Biotechnologies subsidiary is developing its
proprietary GelSite(R) technology designed to provide controlled release of
peptide and protein-based drugs. Carrington's technology is protected by
more than
'/>"/>
| SOURCE Carrington Laboratories, Inc. Copyright©2007 PR Newswire. All rights reserved |